Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Kronos Bio, Inc.
  6. News
  7. Summary
    KRON   US50107A1043

KRONOS BIO, INC.

(KRON)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kronos Bio, Inc.(NasdaqGS:KRON) added to NASDAQ Biotechnology Index

12/20/2021 | 12:00am EDT
share with twitter
share with LinkedIn
share with facebook

Kronos Bio, Inc. has been added to NASDAQ Biotechnology Index.


© S&P Capital IQ 2021
All news about KRONOS BIO, INC.
05/24Goldman Sachs Adjusts Price Target for Kronos Bio to $23 From $35, Reiterates Buy Ratin..
MT
05/23Piper Sanler Lowers Kronos Bio's Price Target to $13 From $30, Maintains Overweight Rat..
MT
05/20INSIDER BUY : Kronos Bio
MT
05/17Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
GL
05/17Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
GL
05/12Kronos Bio to Feature Entospletinib, Lanraplenib Investigational Inhibitors at European..
MT
05/12Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Feature..
GL
05/12Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Feature..
GL
05/04KRONOS BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
05/04Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results
GL
More news
Analyst Recommendations on KRONOS BIO, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -155 M - -
Net cash 2022 73,0 M - -
P/E ratio 2022 -1,18x
Yield 2022 -
Capitalization 191 M 191 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 96
Free-Float 85,5%
Chart KRONOS BIO, INC.
Duration : Period :
Kronos Bio, Inc. Technical Analysis Chart | KRON | US50107A1043 | MarketScreener
Technical analysis trends KRONOS BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,36 $
Average target price 22,25 $
Spread / Average Target 562%
EPS Revisions
Managers and Directors
Norbert W. Bischofberger President, Chief Executive Officer & Director
Yasir B. Al-Wakeel CFO & Head-Corporate Development
Arie S. Belldegrun Chairman
Jorge DiMartino Chief Medical Officer & EVP-Clinical Development
Christopher Dinsmore Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
KRONOS BIO, INC.-75.28%191
MODERNA, INC.-48.48%52 047
LONZA GROUP AG-28.07%42 228
IQVIA HOLDINGS INC.-27.93%38 488
SEAGEN INC.-11.73%25 121
ICON PUBLIC LIMITED COMPANY-31.56%17 232